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Purpose: This trial evaluated the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) with a contemporary
endograft system compared with open surgical repair (open) of descending thoracic aortic aneurysms and large ulcers.
Methods: Forty-two international trial sites enrolled 230 subjects with descending thoracic aortic aneurysms or ulcers. The
study compared 160 TEVAR subjects treated with the Zenith TX2 Endovascular Graft (William Cook Europe, ApS,
Bjaeverskov, Denmark) with 70 open subjects. Subjects were evaluated preprocedure, predischarge, 1, 6, and 12 months,
and yearly through 5 years with medical examination, laboratory testing, chest radiographs, and computed tomography
scans. Mortality rates, prespecified severe morbidity composite index, major morbidity, clinical utility, aneurysm rupture,
and secondary interventions were compared. The TEVAR subjects were evaluated by a core laboratory for device
performance, including change in aneurysm size, endoleak, migration, and device integrity.
Results: The 30-day survival rate was noninferior (P< .01) for the TEVAR group compared with the open group (98.1%
vs 94.3%). The severe morbidity composite index was lower for TEVAR (0.2  0.7 vs 0.7  1.2; P < .01). Cumulative
major morbidity scores were significantly lower at 30 days for the TEVAR group compared with the open group (1.3 
3.0 vs 2.9  3.6, P < .01). The TEVAR patients had fewer cardiovascular, pulmonary, and vascular adverse events,
although neurologic events were not significantly different. Clinical utility for the TEVAR patients was superior to that
of the open patients. No ruptures or conversions occurred in the first year. Reintervention rates were similar in both
groups. At 12 months, aneurysm growth was identified in 7.1% (8/112), endoleak in 3.9% (4/103), migration (>10
mm) in 2.8% (3/107), and other device issues were rare. None of the patients with migration experienced endoleak,
aneurysm growth, or required a secondary intervention.
Conclusions:Thoracic endovascular aortic repair with the TX2 is a safer and effective alternative to open surgical repair for
the treatment of anatomically suitable descending thoracic aortic aneurysms and ulcers at 1 year of follow-up. Device
performance issues are infrequent, but careful planning and regular follow-up with imaging remain a necessity. ( J Vasc
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doi:10.1016/j.jvs.2007.10.032Thoracic endovascular aortic repair (TEVAR) is evolv-
ing at a rapid pace and has the potential to revolutionize the
treatment of thoracic aneurysms, similar to the develop-
ment of open surgical repair. The estimated incidence of
thoracic aortic aneurysms is approximately6/100,000person-
years, the risk of rupture for large aneurysms is up to 74% in
patients without repair, and 90% of patients do not sur-
vive rupture.1
Dedicated clinicians have refined open surgical repair over
decades and have developed a better understanding of spinal
cord injury and techniques to mitigate this risk.2 These con-
certed efforts have resulted in significant improvement in the
care of patientswith thoracic aneurysms, but open repair is still
associated with considerable morbidity and mortality in the
elective and emergency setting, which has led physicians to
seek improved and less invasive methods of treatment.3-6
Although TEVAR offers potential for aneurysm exclusion
while avoiding thoracotomy and aortic cross-clamping with
the resulting sequelae, careful clinical trials are necessary to
fully evaluate this new technology.
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Endovascular Graft (William Cook Europe, ApS, Bjaevers-
kov, Denmark), has been in clinical use for several years and
has undergone several iterations of the implant and delivery
system. Single-center experience with the device shows
promising results for feasibility and safety.7 We designed
and conducted a nonrandomized, controlled, multicenter,
international trial to compare outcomes between patients
treated by TEVARwith the TX2 and open repair to support
regulatory approval of this device in the United States. The
1-year analyses are presented in this article. We had free
access to the data, analyzed the data in concert with the
sponsor, interpreted the analyses, wrote and edited the
manuscript, and selected the presentation venue and jour-
nal submission.
MATERIAL AND METHODS
Detailed description of the TEVAR device, deploy-
ment system, trial design with inclusion and exclusion
criteria, definitions, repair techniques, and statistical analy-
sis has been published.8
Device description. Briefly, the Zenith TX2 Endovas-
cular Graft is a one- or two-piece tubular endovascular
graft. The stent grafts are constructed of full-thickness
woven polyester fabric sewn to self-expanding stainless steel
Cook Z Stents with braided polyester and monofilament
polypropylene suture. The TX2 device is fully stented to
provide stability and the expansile force necessary to open
the lumen of the graft during deployment. In addition, the
Cook Z Stents contain barbs at the distal and proximal ends
to augment the necessary attachment and seal of the graft
to the vessel wall. The deployment system allows staged,
rapid placement of the TX2 in the often-tortuous thoracic
aorta from a transfemoral approach.
Trial design. The study is a nonrandomized, con-
trolled, multicenter, international trial designed to evaluate
the safety and effectiveness of the TX2, a contemporary
thoracic aortic endograft, in patients with descending tho-
racic aneurysms 5 cm, rapid growth 5 mm/y, or ulcers
10 mm in depth and 20 mm in diameter. Type I thora-
coabdominal aneurysms were eligible if the placement of
endograft fabric was planned to be above the visceral vessels
or if there was no plannedmesenteric revascularization with
open repair. The primary end points were 30-day survival
and 30-day rupture-free survival. Secondary end points
included 30-day morbidity and clinical utility.
Definitions. Fifty-seven prespecified events were con-
sidered in calculating a composite morbidity score (Table I).
Because all 57 events were weighted equally when calculat-
ing the composite score, but not of the same clinical
severity, a subset of severe morbid events (Table II) were
identified in part from reporting standards for endovascular
aneurysm repair.9 These were considered in calculating a
severe morbidity composite index that would be more
clinically relevant when endovascular and open aortic repair
operations were compared.● Endoleaks were classified as types I through IV according
to the standard definitions.10
● Device migration was defined as caudal or cranial move-
ment of the proximal or distal components of the endo-
prosthesis10 mm relative to anatomic landmarks iden-
tified on the first technically adequate postoperative
computed tomography (CT) scan.9
● Aneurysm sac size change was evaluated by comparing
the major axis (or ulcer depth for ulcers) obtained from
the three-dimensional (3D) reconstructed image per-
pendicular to the centerline of flow demonstrating the
largest major diameter from the first postoperative CT
scan to CT scans obtained at subsequent time points.
● An increase in size was defined as an increase 5 mm in
the major diameter.
Device integrity was assessed using chest radiograph
and 3D reformatted CT imaging.
Repair techniques. The endovascular and open surgi-
cal aneurysm/ulcer repair techniques consisted of institu-
tional standard of care executed within the limits of the
study protocol.
Statistical analysis. Analyses were performed using
SAS 8.2 software (SAS Institute, Cary, NC) and have been
described in detail previously.8 Continuous variables were
reported as means and standard deviations unless otherwise
noted, and P values were calculated using standard t tests.
Dichotomous and polytomous variables were reported as
percentages, and P values were calculated using the Fisher
exact test. Propensity score analysis was used to account for
variables with the potential to influence outcome, such as
age, sex, and American Society of Anesthesiologists (ASA)
class, and confirm the results of statistical comparison for
each primary and secondary study end point. Specifically, a
propensity score was calculated for each patient and then
used as a covariate in a statistical model to assess the
treatment effect in the presence of the propensity score.
RESULTS
Enrollment began on March 30, 2004, and was com-
pleted on July 6, 2006. The results reported here reflect
data received as of September 12, 2007. A total of 160
patients for endovascular repair and 70 patients for open
surgical repair were enrolled at 42 institutions. Enrollment
for 51 of 70 open patients (73%) was retrospective, but the
treatment groups were reasonably concurrent, with 81% of
open patients treated within the period of TEVAR enroll-
ment.
Patient characteristics. Evaluation of pre-existing
conditions or risk factors showed similar preoperative de-
mographic, medical, and laboratory characteristics in the
TEVAR and open study groups, with a few exceptions. As
summarized in Table III, patients in the TEVAR group
were older (P .01), weighed more (P .02), had a larger
body mass index (P  .03), and had more previous access
site surgery (P  .02), whereas patients in the open group
had a higher incidence of prior thoracic surgery or trauma
(P .01). The preprocedure hemoglobin (g/dL) was higher
ation
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vs 13.0 1.6,P .03); however, both values were within the
normal range for hemoglobin measurements. The TEVAR
patients had a lower ASA classification (P  .01) and higher
Society for Vascular Surgery/International Society for Car-
Table I. All events comprising the composite morbidity sc
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57. Wound complicdiovascular Surgery risk score (P .03).Aneurysm/ulcer characteristics. Both the endovas-
cular treatment group and open surgical control group had
patients with aneurysms (86% and 90%) and patients with
ulcers (14% and 10%), with the distribution in morphology
being similar between the two groups (P  .40). As sum-
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different between groups (P  .02). Specifically, the per-
centage of patients with a proximal location was lower in
the TEVAR group compared with the open group (22.5%
vs 36.9%). Themajor axis diameter of the aneurysmwas not
different between the two groups (P .20; Table IV), but
the ulcer depth was smaller for the TEVAR group than the
open group (14  4.7 mm vs 21  7.8 mm, P  .01).
Protocol-driven anatomic differences included smaller
mean neck diameters, such as at 30 mm distal to the left
common carotid artery (P  .01) and 30 mm proximal to
the celiac axis artery (P  .01), in the TEVAR group
compared with the open group.
Procedure details. All patients in the open group
required general anesthesia, while in the TEVAR group,
71.3% received general and 28.7% had regional anesthesia
(P  .01). An access conduit was used for device insertion
in 9.4% (15 of 160), which included 14 patients with an
iliac conduit and one patient with an aortic conduit. A
cutdown was used for device insertion in 88.1% (141 of
160), and percutaneous access was used in 2.5% (4 of 160).
The endovascular graft was successfully implanted in 98.8%
(158 of 160) of patients. In one case, the implanting
physician decided not to perform a previously planned
access conduit owing to small access vessels and calcifica-
tion and terminated the case without attempting to insert
the introducer. In the second case, advancing the intro-
ducer through the iliac limb of an in situ open abdominal
aortic aneurysm graft was not possible.
Of the 158 TX2 patients who were successfully treated,
59.5% (94 of 158) received a two-piece device and 40.5%
(64 of 158) received a one-piece device, consisting of a
Table II. Events comprising the severe morbidity
composite index
Organ system Event
Cardiovascular 1. Q-wave myocardial infarction
2. Cardiac event involving arrest, resuscita-
tion, or balloon pump
Pulmonary 3. Ventilation 72 hours or reintubation
4. Pulmonary event requiring tracheos-
tomy or chest tube
Renal 5. Permanent dialysis, hemofiltration, or
kidney transplant
Gastrointestinal 6. Bowel resection
Neurologic 7. Stroke or severe impairment (paraple-
gia)
Vascular 8. Amputation involving more than the
toes
9. Aneurysm or vessel leak requiring reop-
eration
10. Deep vein thrombosis requiring surgical
or lytic therapy
11. Pulmonary embolism involving hemo-
dynamic instability
12. Coagulopathy requiring surgery
Wound 13. Wound complication requiring return
to the operating roomproximal main body component in 38.0% (60 of 158), aone-piece main body component in 1.9% (3 of 158), and
a proximal main body extension in 0.6% (1 of 158).
The use of spinal cord protection was at the physician’s
discretion. A spinal drain was used in 25.6% (41 of 160) of
patients in the TEVAR group compared with 77.1% (54
of 70) in the open group. In addition, 34.3% (24 of 70) of
open patients had some variation of hypothermia, and
31.4% (22 of 70) had distal aortic perfusion for spinal cord
protection.
Procedure time was shorter with TEVAR compared
with open (114  46 minutes vs 244  92 minutes, P 
.01). The anesthesia time was also shorter for TEVAR
compared with open (183  67 minutes vs 366  125
minutes, P  .01). The cross-clamp time for the open
group was 44  28 minutes.
The distribution in proximal graft location was not
significantly different between groups. In one open patient,
the graft was sewn proximal to the left common carotid
artery (LCCA), which required hypothermic circulatory
arrest; this maneuver was unplanned. In the open group,
4.3% (3 of 70) underwent hypothermic circulatory arrest
during aneurysm repair.
The distribution in distal graft location was different
between groups (P  .01). All patients in the TEVAR
group had a distal graft location that was proximal to the
celiac artery. The distal graft location was above the celiac
artery in 66 open patients (94.3%) and below the celiac
artery in 4 (5.7%); and of these, only one patient required
mesenteric vessel reconstruction of the celiac axis, superior
mesenteric artery, and right renal artery; the graft was
beveled in the other three. Procedural blood loss (216 
293 mL vs 2538  2179 mL, P  .01) and the need for
packed red blood cells (3.1% vs 87.1%, P  .01) were lower
for TEVAR compared with open repair.
Six open patients underwent hypothermic circulatory
arrest, had a proximal graft location above the LCCA, or
had a distal graft location below the celiac. Recognizing
that inclusion of open surgical control patients with these
characteristics could potentially bias outcome in favor of
TEVAR, subanalyses were performed in which these pa-
tients were excluded from the primary and secondary end
point comparisons. The subanalyses confirmed that there
was no effect on outcome resulting from the inclusion of
the open surgical control patients with any of these three
factors. Therefore, these six open patients were included in
the analyses.
Mortality. The 30-day survival estimate from all-cause
mortality was noninferior (P  .01) in the endovascular
treatment group compared with the open surgical control
group (98.1% vs 94.3%). Propensity score analysis con-
firmed noninferior 30-day survival for the endovascular
treatment group. The 365-day survival estimate from all-
cause mortality was 91.6% in the endovascular group and
85.5% in the open surgical group, as illustrated in Fig 1
(log-rank  0.15). The 365-day survival estimate from
aneurysm-related mortality was 94.2% in the endovascular
group and 88.2% in the open surgical group, as illustrated
in Fig 2 (log-rank  0.12). All aneurysm-related deaths
ascula
mean
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committee, and no deaths were considered device-related.
Severe morbidity composite index. The 30-day se-
vere morbidity composite index (cumulative mean number
of events per patient) was markedly lower in the endovas-
cular treatment group compared with the open surgical
control group (0.2  0.7 vs 0.7  1.2; P  .01). The
percentage of patients who experienced a severemorbid event
was more than one-third lower with TEVAR compared with
open repair (9.4% vs 33%, P  .01). Kaplan-Meier estimates
for freedom from individual severe morbid events at 365 days
were significantly lower (P  .05) in the open group com-
pared with the TEVAR group for ventilation 72 hours,
pulmonary event requiring tracheostomy or chest tube, rein-
Table III. Patient demographics, medical history, and risk
Item TEVA
Sex, male 72 (115
Age, years 72  9.
Weight, kg 80.5  16
Body mass index 27.2  4.
Cardiovascular
Myocardial infarction 22 (35/
Congestive heart failure 13 (20/
Coronary artery disease 44 (69/
Arrhythmia 30 (48/
Vascular
Thromboembolic event 10 (16/
Peripheral vascular disease 24 (39/
Family history of aneurysm 17 (24/
Hypertension 89 (143
Thoracic surgery/trauma 10 (16/
Diagnosed AAA 31 (50/
Repaired AAA 19 (31/
COPD 45 (71/
Renal failure requiring dialysis 3.1 (5/1
Diabetes mellitus 19 (30/
Sepsis 1.9 (3/1
Neurologic
Cerebrovascular accident 15 (24/
Carotid endarterectomy 5.7 (9/1
Gastrointestinal disease 41 (64/
Liver disease 6.3 (10/
Cancer 25 (40/
Excessive alcohol use 3.2 (5/1
Tobacco use
Current smoker 22 (35/
Quit smoking 66 (103
Never smoked 12 (18/
Access site
Previous surgery 10 (16/
Previous radiation 0.0 (0/1
Allergies 44 (70/
ASA classification
Healthy patient: 1 8.8 (14/
Mild systemic disease: 2 50 (80/
Severe systemic disease: 3 37 (59/
Incapacitating systemic disease: 4 4.4 (7/1
Moribund patient: 5 0 (0/16
Total SVS/ISCVS risk score 6.4  3.
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesi
SVS/ISCVS, Society for Vascular Surgery/International Society for Cardiov
*Categoric data are presented as percentages (No.), and continuous data astubation, stroke, and paraplegia (Table V).All morbidity. Cardiovascular (P  .01), pulmonary
(P  .01), and vascular (P  .01) categories of morbid
events were lower in the endovascular treatment group
compared with the open surgical control group (Table VI).
The composite 30-day morbidity score (mean number of
events per patient) was lower with TEVAR compared with
open repair (1.3  3.0 vs 2.9  3.6; P  .01). Propensity
score analysis confirmed lower 30-day morbidity for the
endovascular treatment group. The percentage of patients
experiencing at least one morbid event was also lower with
TEVAR compared with open (41.9% vs 68.6%, P  .01).
Neurologic morbidity. An assessment of neurologic
morbidity consisted of evaluating five prespecified events:
carotid artery embolization/occlusion, stroke, transient
ssment
Open* P
) 60 (42/70) .09
0) 68  12 (70) .01
8) 75.9  15 (70) .02
3) 25.9  3.7 (69) .03
25 (17/68) .73
12 (8/69) .99
42 (29/69) .88
19 (13/69) .1
8.7 (6/69) .99
26 (18/69) .86
20 (11/54) .67
) 83 (58/70) .19
26 (18/70) .01
23 (16/70) .2
14 (10/70) .47
43 (30/70) .88
2.9 (2/70) .99
14 (10/70) .45
1.5 (1/68) .99
15 (10/68) .99
2.9 (2/70) .51
30 (21/70) .14
4.3 (3/70) .75
16 (11/70) .12
0.0 (0/67) .32
.19
18 (12/68)
) 62 (42/68)
21 (14/68)
1.4 (1/69) .02
0.0 (0/69) NA
40 (28/70) .66
.01
7.1 (5/70)
41 (29/70)
29 (20/70)
23 (16/70)
0 (0/70)
9) 5.4  3.5 (68) .03
ts; NA, not applicable; TEVAR, thoracic endovascular aneurysm repair;
r Surgery.
 standard deviation (No.).asse
R*
/160
6 (16
(15
9 (15
158)
160)
158)
159)
159)
160)
140)
/160
160)
160)
160)
159)
60)
160)
56)
160)
59)
158)
160)
159)
57)
156)
/156
156)
159)
59)
160)
160)
160)
160)
60)
0)
0 (15
ologisischemic attack (TIA)/reversible ischemic neurological
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ity weakness but still able to walk). Table VII reviews the
percentage of patients experiencing each of these categories
of neurologic events 30 days.
Stroke. Stroke occurred in four TEVAR patients; all
had general cardiovascular risk factors, none had history of
TIA or carotid endarterectomy, all had proximal location of
the graft distal to the left subclavian artery, one had a brain
Table IV. Core laboratory analysis of preprocedure anato
Item TEVARa
Morphology type
Aneurysm 86 (137/160)
Ulcer 14 (23/160)
Morphology location
Proximal 23 (36/160)
Middle 55 (88/160)
Distal 23 (36/160)
Dimensions, mm
Aneurysm major axis 60.8  10.7 (137)
Ulcer depth 14.4  4.7 (22)
Proximal neckb 35.5  7.8 (158)
Distal neckc 32.3  5.0 (157)
TEVAR, Thoracic endovascular aneurysm repair.
aCategoric data are presented as percentages (No.), and continuous data as
bMajor axis at 30-mm distal to left common carotid artery.
cMajor axis at 30-mm proximal to celiac axis artery.
Fig 1. All-cause mortality survival curves.
Fig 2. Aneurysm-related mortality survival curves.biopsy 11 days after TEVAR, and three of the patients died.Paraplegia. Two TEVAR patients experienced para-
plegia after treatment of the aneurysm. The aneurysms in
both patients were in the mid-descending thoracic aorta,
there was no history of abdominal aneurysm repair, the
proximal aspect of the grafts were deployed distal to the left
subclavian artery, and no spinal drains were used. In the first
patient, approximately 70% of the descending aorta was
covered by the graft and paraplegia developed on postop-
erative day 0; in the second patient (who also had a stroke),
approximately 100% of the descending aorta was covered
by the graft and paraplegia developed on postoperative day
3. Both patients died.
Paraparesis. Seven patients in the TEVAR group were
diagnosed with paraparesis30 days. Four had a history of
AAA repair, three had a spinal drain placed, and two had a
proximal graft location that was proximal to the left subcla-
vian artery (one did and one did not have subclavian
revascularization). One patient died without resolution of
the paraparesis at postoperative day 37 of septicemia com-
plicated by respiratory failure. Paraparesis resolved in the
other six patients.
Clinical utility. As some might expect from a less-
invasive procedure, all clinical utility measures were supe-
rior in the TEVAR group compared with the open surgical
repair group (Table VIII). Propensity score analysis con-
firmed superior clinical utility in the TEVAR group.
Rupture. There were no early or late ruptures with
either TEVAR or open through 365 days.
Secondary interventions. The percentage of patients
requiring reintervention through 12 months was similar
(P .74) for endovascular repair (4.4%, 7 of 158) and open
surgical repair (5.7%, 4 of 70), and included three endovas-
cular patients and three open surgical patients requiring
secondary intervention 7 days of the initial aneurysm
repair. In the TEVAR group, seven patients underwent
secondary interventions, including one patient who under-
went two secondary interventions for treatment of a distal
type I endoleak (bare stent placement and stent place-
Opena P
.4
90 (63/70)
10 (7/70)
.02
37 (24/65)
52 (34/65)
11 (7/65)
63.0  10.8 (53) .2
20.7  7.8 (7) .01
41.2  9.9 (55) .01
41.5  13.5 (56) .01
 standard deviation (No.).my
meanment/coil embolization/distal extension placement). The
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30 days 365 days
Event Parameter TEVAR Open TEVAR Open
Q-wave myocardial infarction Number at riska 160 70 156 66
Cumulative events 0 0 0 0
Cumulative censoredb 4 4 41 17
Kaplan-Meier est.c 1 1 1 1
Standard error 0 0 0 0
Cardiac event involving arrest,
resuscitation or balloon pump
Number at riska 160 70 153 66
Cumulative events 4 1 4 2
Cumulative censoredb 3 3 38 15
Kaplan-Meier est.c 0.98 0.99 0.98 0.97
Standard error 0.01 0.01 0.01 0.02
Ventilation 72 hoursd Number at riska 160 70 155 57
Cumulative events 1 11 1 11
Cumulative censoredb 4 2 40 13
Kaplan-Meier est.c 0.99 0.84 0.99 0.84
Standard error 0.01 0.04 0.01 0.04
Reintubationd Number at riska 160 70 150 57
Cumulative events 8 10 8 11
Cumulative censoredb 2 3 35 12
Kaplan-Meier est.c 0.95 0.86 0.95 0.84
Standard error 0.02 0.04 0.02 0.04
Pulmonary event requiring tracheotomy or
chest tubed
Number at riska 160 70 154 59
Cumulative events 2 9 4 12
Cumulative censoredb 4 2 38 9
Kaplan-Meier est.c 0.99 0.87 0.97 0.82
Standard error 0.01 0.04 0.01 0.05
Permanent dialysis or transplante Number at riska 160 70 156 66
Cumulative events 0 0 0 0
Cumulative censoredb 4 4 41 17
Kaplan-Meier est.c 1 1 1 1
Standard error 0 0 0 0
Bowel resection Number at riska 160 70 153 65
Cumulative events 3 1 5 1
Cumulative censoredb 4 4 38 17
Kaplan-Meier est.c 0.98 0.99 0.97 0.99
Standard error 0.01 0.01 0.01 0.01
Stroked Number at riska 160 70 153 63
Cumulative events 4 6 5 7
Cumulative censoredb 3 1 38 13
Kaplan-Meier est.c 0.98 0.91 0.97 0.9
Standard error 0.01 0.03 0.01 0.04
Paraplegiad Number at riska 160 70 155 63
Cumulative events 2 4 2 4
Cumulative censoredb 3 3 39 13
Kaplan-Meier estc 0.99 0.94 0.99 0.94
Standard error 0.01 0.03 0.01 0.03
Pulmonary embolism involving
hemodynamic instability or surgery
Number at riska 160 70 156 66
Cumulative events 0 0 0 0
Cumulative censoredb 4 4 41 17
Kaplan-Meier est.c 1 1 1 1
Standard error 0 0 0 0
Aneurysm or vessel leak requiring
reoperation
Number at riska 160 70 156 65
Cumulative events 0 1 0 1
Cumulative censoredb 4 4 41 17
Kaplan-Meier est.c 1 0.99 1 0.99
Standard error 0 0.01 0 0.01
Amputation involving more than toes Number at riska 160 70 156 66
Cumulative events 0 0 0 1
Cumulative censoredb 4 4 41 16
Kaplan-Meier est.c 1 1 1 0.98
Standard error 0 0 0 0.02
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imal type I endoleak (proximal main body extension place-
ment), distal type I endoleak (molding balloon angioplasty
and distal extension placement), type III endoleak (angio-
gram to rule out endoleak), iliac artery occlusion (femoro-
femoral bypass), aneurysm growth but no detectable en-
Table V. Continued
Event Paramet
Deep vein thrombosis requiring surgery
or lytic therapy
Number at ris
Cumulative ev
Cumulative ce
Kaplan-Meier
Standard error
Coagulopathy requiring surgery Number at ris
Cumulative ev
Cumulative ce
Kaplan-Meier
Standard error
Wound complication requiring return
to operating room
Number at ris
Cumulative ev
Cumulative ce
Kaplan-Meier
Standard error
TEVAR, Thoracic endovascular aneurysm repair.
aNumber of patients at risk at the beginning of the interval.
bTotal censored patients up to and including the specific interval.
cMade at end of interval.
eFollowing normal serum creatinine.
dP (log-rank)  .05 at 365 days.
Table VI. Morbid events (by category) occurring 30
days
Category TEVAR, % (No.) Open, % (No.) P
Cardiovascular 15.6 (25/160) 44.3 (31/70) .01
Pulmonary 15.6 (25/160) 44.3 (31/70) .01
Renal 8.8 (14/160) 14.3 (10/70) 0.24
Gastrointestinal 6.9 (11/160) 7.1 (5/70) .99
Neurologic 8.1 (13/160) 14.3 (10/70) .15
Vascular 22.5 (36/160) 40 (28/70) .01
Wound 6.3 (10/160) 4.3 (3/70) .75
TEVAR, Thoracic endovascular aneurysm repair.
Table VII. Neurologic events occurring 30 days
Event TEVAR, % (No.) Open, % (No.) P
Carotid artery
embolization/occlusion
0 (0/160) 0 (0/70) —
Stroke 2.5 (4/160) 8.6 (6/70) .07
TIA/RIND 0.6 (1/160) 1.4 (1/70) .51
Paraplegia 1.3 (2/160) 5.7 (4/70) .07
Paraparesis 4.4 (7/160) 0 (0/70) .10
TEVAR, Thoracic endovascular aneurysm repair.doleak (distal extension placement in overlap and distal endof in situ graft), and a proximal aortic pseudoaneurysm
(proximal extension placement). There were no open con-
versions in the TEVAR group through 365 days. Three
open surgical control patients underwent re-exploration for
bleeding, and one underwent custom endograft placement
for an aortoesophageal fistula.
Change in aneurysm or ulcer size. At 12 months,
aneurysm/ulcer size decreased for 48% (54 of 112) of the
patients and remained unchanged for 45% (50 of 112).
Aneurysm growth was identified in 7.1% (8 of 112) at 12
months. Two of these patients have had follow-up at 24
months and do not have sac growth compared with base-
line, one has been re-treated for distal type I endoleak, one
has been re-treated for growth, and four have not had
further follow-up. In the latter four patients, there is no
detectable endoleak at 12 months or evidence of graft
infection, but the aortic neck diameter at the actual graft
placement does not meet the recommended oversizing of
at least 10%. Each of these four patients also has an inverted
funnel-shaped proximal aortic neck or a funnel-shaped
distal neck.
Endoleak. Endoleak rates at predischarge, 30 days, 6
months, and 12 months were 13%, 4.8%, 2.6%, and 3.9%
(Table IX). Several patients had reintervention in the first
year such that no patients were identified with type I or IV
endoleak at 12 months. One patient with a one-piece
system has a type III endoleak at 12months (unknown type
per site assessment) that was not associated with aneurysm
growth and has not had subsequent imaging or reinterven-
tion.
Migration. Proximal or distal graft migration of 10
30 days 365 days
TEVAR Open TEVAR Open
160 70 156 66
0 0 1 0
db 4 4 40 17
1 1 0.99 1
0 0 0.01 0
160 70 156 65
0 1 0 1
db 4 4 41 17
1 0.99 1 0.99
0 0.01 0 0.01
160 70 156 66
0 0 2 0
db 4 4 41 17
1 1 0.99 1
0 0 0.01 0er
ka
ents
nsore
est.c
ka
ents
nsore
est.c
ka
ents
nsore
est.cmm was noted in 2.8% (3 of 107) through 12 months,
0 (0/
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graft and one case of cranial migration of the distal graft.
None have been associated with endoleak or increase in
aneurysm size, and none have had secondary intervention.
All three patients have aortic neck diameter at the actual
graft placement that does not meet the recommended
oversizing of at least 10%. All three also have placement of
the pertinent barbed stent in a neck that is either an acutely
angled segment or in an area of thrombus.
Device integrity. Device integrity was assessed at each
examination period through 12 months. None of the pa-
tients have had stent fracture, barb separation, stent-to-
graft separation, or component separation. One patient
(0.8%) has distal bare stent strut entanglement from
predischarge through 12 months, which is not associated
with migration, endoleak, or the need for secondary
intervention. It is unclear whether the entanglement is
related to a device failure, barb entanglement during
loading, movement during deployment, or very tortuous
anatomy.
Device patency. No patients have had loss of patency
through 12months. A kink was noted in 1.6% (2 of 123) of
patients at 12 months and compression was noted in 0.9%
(1 of 108), but none of these three patients have adverse
clinical sequelae or required a secondary intervention. The
compression is a concentric constriction of one mid-body
stent of the device not associated with tortuosity or flow
limitation with expansion of the stents above and below the
Table VIII. Clinical utility measures
Measure TEV
Blood transfusions, No. 0.3  1
Duration of intubation, hours 2.8  4
Duration of ICU stay, days 2.2  6
Days to ambulation 1.6  2
Days to resumption of oral fluid intake 0.7  1
Days to resumption of regular diet 1.9  2
Days to resumption of bowel function 2.9  2
Days to hospital discharge 5.0  8
TEVAR, Thoracic endovascular aneurysm repair.
aData are presented as mean  standard deviation (No.).
Table IX. Percentage of patients with endoleak at each fo
Type Predischarge
Any 12.6 (17/135) 4
Multiple 0 (0/135)
Proximal type I 0 (0/135)
Distal type I 0.7 (1/135) 0
Type IIa 1.5 (2/135) 0
Type IIb 5.9 (8/135) 2
Type III 1.5 (2/135) 0
Type IV 1.5 (2/135)
Unknown 1.5 (2/135)compressed segment. This should be distinguished fromthe phenomena of endovascular graft collapse described in
the literature.11
DISCUSSION
This study was designed to assess the safety and effec-
tiveness of TEVAR with the Zenith TX2 Endovascular
Graft by comparing the mortality, morbidity, and clinical
utility of the two test groups. This study assessed key
variables with respect to device performance in the endo-
vascular treatment group, including change in aneurysm/
ulcer size, endoleak, migration, device integrity, and sec-
ondary interventions.
Overall survival with TEVAR was statistically not infe-
rior to open surgical repair at 30 days and was similar at 1
year. Aneurysm-related survival was also similar in both
groups.
The analysis with the severe composite morbidity index
was prespecified by physicians experienced in thoracic aor-
tic disease treatment and was designed to capture the
sentinel types of complications that are classically reported
in the surgical literature. The index avoids dilution by
less-severe adverse events and focuses on the truly impor-
tant problems that surgeons encounter when treating these
patients (Table II). This trial revealed significantly fewer
sentinel events with TEVAR compared with open repair.
This striking reduction was seen in both the cumulative
number of events per patient (0.2  0.7 vs 0.7  1.2; P 
.01) and the frequency of at least one event (9.4% vs 33%,
Opena P
60) 1.7  1.9 (70) .01
47) 53.1  85.4 (66) .01
53) 9.4  16.9 (70) .01
48) 5.5  5.6 (63) .01
55) 4.0  5.6 (60) .01
56) 5.2  3.7 (58) .01
4) 5.5  3.3 (61) .01
59) 16.1  18.7 (70) .01
up time point based on core lab analysis
Time point, % (No.)
ays 6 months 12 months
/126) 2.6 (3/114) 3.9 (4/103)
126) 0 (0/114) 0 (0/103)
126) 0 (0/114) 0 (0/103)
/126) 0.9 (1/114) 0 (0/103)
/126) 0 (0/114) 0 (0/103)
/126) 1.8 (2/114) 1.9 (2/103)
/126) 0 (0/114) 1.0 (1/103)
126) 0 (0/114) 0 (0/103)
126) 0 (0/114) 1.0 (1/103)ARa
.0 (1
.6 (1
.2 (1
.5 (1
.9 (1
.7 (1
.3 (9
.6 (1llow-
30-d
.8 (6
0 (0/
0 (0/
.8 (1
.8 (1
.4 (3
.8 (1
0 (0/P  .01).
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30-days was lower in the patients receiving endovascular
treatment than the patients having open surgical repair.
The cumulative number of events per patient was lower
with TEVAR, as well as the chance of having at least one
adverse event. The reduction with TEVAR was primarily in
fewer cardiovascular, pulmonary, and vascular adverse
events.
Stroke and paraplegia remain critical clinical concerns
that are often fatal after descending thoracic aneurysm
repair. These are well-recognized complications associated
with open surgical repair that result from insult to the brain
or spinal cord. Endovascular repair also has risk of stroke
because instrumentation of the arch is often necessary and
stroke may be caused from air or atheroma that embolize to
the brain. Similarly, spinal cord damage is a known compli-
cation with TEVAR, although it may more often be a
partial deficit, be delayed in onset, and has improved in
some patients.17,18
Although not statistically different, the point estimates
of patients experiencing the most debilitating permanent
neurologic events 30 days are intriguing (Table VII);
specifically, the percentage of stroke (2.5% vs 8.6%, P 
.07) and paraplegia (1.3% vs 5.7%, P  .07) 30 days
trended lower with TEVAR with the TX2 compared with
open repair. However, more TEVAR patients experienced
paraparesis, defined as weakness but still able to walk (4.4%
vs 0%, NS). These rates are interesting because there are
more than double the percentage of distal thoracic aneu-
rysms in the TEVAR group compared with the open group.
In contrast to the spinal ischemic event rate with open
repair reported in other multicenter TEVAR studies,12 the
rate of spinal ischemic events in the open group from this
study appeared to be largely comparable with those re-
ported in several large single-center experiences (1.5%-
6.3%),2,6,13-15 even though 28 institutions contributed at
least one open patient. Nonstatistically significant differ-
ences between open and TEVAR in spinal ischemic events
have been reported previously.16,17 Clearly, more knowl-
edge about these rare events is needed, and larger, higher-
powered studies will be required to prove if such specific
complications are more or less frequent with TEVAR.
The benefits in clinical utility with TEVAR are often
overlooked because of focus on survival and neurologic
disability. Nonetheless, all measures of clinical utility were
substantially better with TEVAR compared with open sur-
gical repair. These advantages of less invasive treatment
have been frequently confirmed in other literature re-
ports.12,16,17 These factors often weigh importantly in the
decision making of patients and their families who may be
taking care of them during a prolonged recovery.
The evaluation of effectiveness for TEVAR includes
hard end points (rupture and reinterventions) and surro-
gates that may predict later effectiveness (core laboratory
assessment of device performance). There were no aneu-
rysm ruptures in either group, and no immediate or delayed
conversions to open repair through 1 year. Reintervention
rates were similar in both groups, and no unusual motivesor types of reinterventions were encountered.17 Core lab-
oratory assessment of rates of aneurysm sac change, en-
doleak, migration, device integrity, and loss of patency
were all suitably low.18,19
Most type I and III endoleaks were addressed in the
first year with endovascular reintervention, and none re-
quired conversion. Endotension may be related to unde-
tectable endoleak through the seal zone or transfer of
pressure to the aneurysm by thrombus in the seal zone and
was associated with adverse neck anatomy and sizing that
did not meet recommended guidelines. Migration was
similarly associated with adverse neck anatomy and sizing
that did not meet recommended guidelines. Further study
with longer follow-up will help definitively identify specific
etiologies for these infrequent events, although at the
1-year time point, it appears that proper selection and
assessment of neck anatomy, appropriate sizing of devices,
and deployment at the initially targeted neck site may be
important in achieving durable exclusion.
CONCLUSION
One-year results of this trial demonstrate similar overall
and aneurysm-related survival with TEVAR using the TX2
compared with open repair. Significant reductions in severe
and major adverse events contributed to improved clinical
utility with TEVAR compared with open surgical repair.
There were no ruptures or conversions in the endovascular
treatment group, and reintervention rates were similar in
both groups. Radiographic findings of sac enlargement,
endoleak, migration, and other device issues were infre-
quent but underscore the value of careful procedure plan-
ning and regular follow-up with imaging before and after
TEVAR. These 1-year results provide reasonable assurance
that the TX2 is a safer and effective alternative to open
surgical repair. Patient follow-up beyond 1-year remains
on-going and is essential for assessing long-term perfor-
mance and the durability of these early benefits.
We gratefully acknowledge the contributions of the
study site investigators and coordinators (see Appendix,
online only), MED Institute for its assistance in the prepa-
ration of this article, and the core laboratory.
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Dr Steven Rivers (Bronx, NY): I have been intrigued and
impressed with the absence of spinal cord ischemia in the TEVAR
patients and in several other reports of similar endovascular treat-
ment of thoracic aneurysms. It makes me wonder if for the patients
that we still need to do open repairs on, are we wasting our time
doing intercostal reimplantations? Are we wasting our time with
spinal cord fluid measurements and various other procedures that
we have been doing to alleviate some of the problems with open
repair? But particularly, intuitively, we have always reimplanted as
many of these vessels as we can and, I mean, are we wasting our
time? And also, could you comment on whether or not there were
any specific protocols for your open repair techniques.
Dr Jon S. Matsumura: The incidence of paraplegia is not
zero with TEVAR. It does occur, and paraparesis with partial
weakness also occurs after TEVAR. However, it is my impression
that it is less frequent than in open repair. Nevertheless, we use
adjuncts per institutional protocol. In this trial, 26% of the TEVAR
patients had a spinal drain placed, and most institutions keep the
mean arterial pressure elevated.
With TEVAR, one cannot reimplant the intercostal vessels,
but one does have to decide on what to do when covering the left
subclavian artery, which provides the upper cord with some collat-
eral supply. Unlike a previous trial, we did not have a policy to
routinely revascularize the subclavian artery if it was covered in this
trial. In my own center, it is a routine practice to do it. Based on
EuroSTAR [European Collaborators on Stent/Graft Techniques
for Aortic Aneurysm Repair] data presented earlier, many centerslarization is helpful in TEVAR, that suggests that we are not
wasting our time with intercostal reimplantation with open repair.
The open repair techniques in this trial were also per institu-
tional protocol and not standardized, other than we excluded
planned deep hypothermic circulatory arrest. About 80% had
spinal cord protection, and that included epidural cooling, spinal
cord drainage, and distal perfusion in the majority of patients.
Dr Amy Reed (Cincinnati, Ohio): Could you share with us
just what you are doing for a preoperative evaluation of the carotids
and vertebrals. Are you just doing a carotid duplex or CT angiog-
raphy or anything specific to try and pick out those patients that
might have problems with stroke postoperatively?
Dr Matsumura: The reality is most TEVAR patients have a
CTA or MRA that images the aortic arch and most of the proximal
carotid and vertebral circulation. Inspecting the arch and carefully
selecting patients is probably important in preventing stroke with
TEVAR, similar to preventing stroke with transfemoral carotid
stenting. Based on my own experience, and that of some expert
colleagues in this room, if you are going to electively cover the left
subclavian with TEVAR, you should revascularize it. Our favorite
method is a transposition, unless they have an internal mammary
artery attached to a coronary artery, in which case we do a carotid–
subclavian bypass. If you do subclavian revascularization routinely,
there is not much benefit to image the distal vertebral or basilar
arteries.
If one practices selective revascularization, I strongly recom-
mend imaging both vertebral arteries and the intracranial circula-
tion. There will be a few patients with abnormalities that will
influence how the left vertebral or left subclavian are treated.
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